What is the current Psychedelic Drugs market size?

The Psychedelic Drugs market size is approximately USD 1.2 billion as of 2023.

What is the growth forecast for the Psychedelic Drugs market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing demand.

What are the key drivers of the Psychedelic Drugs market?

Key drivers include rising mental health awareness and growing research on psychedelic therapies.

What are the major challenges facing the Psychedelic Drugs market?

Challenges include regulatory hurdles and social stigma surrounding psychedelic substances.

Which regions are leading the Psychedelic Drugs market?

North America and Europe are currently leading the market due to favorable regulations.

Who are the top companies in the Psychedelic Drugs market?

Top companies include Compass Pathways and MindMed, which are driving innovation and growth.

What future opportunities exist in the Psychedelic Drugs market?

Future opportunities include expanding treatment options and developing new psychedelic compounds.

How is technology impacting the Psychedelic Drugs market?

Technology is enabling more efficient drug development and improving patient outcomes through digital therapies.

What is the current regulatory landscape for Psychedelic Drugs?

The regulatory landscape is evolving, with many countries reevaluating laws and regulations surrounding psychedelic substances.

What is the future outlook for the Psychedelic Drugs market?

The future outlook is promising, with growing demand and increasing investment in psychedelic research and development.

Psychedelic Drugs Market Comprehensive Report: 200+ Pages | 2026–2034

Psychedelic Drugs by Application (Depressive Disorders, Post-Traumatic Stress Disorders, Substance Abuse Disorders, Obsessive Compulsive Disorders, Others), by Types (Psilocybin, LSD, MDMA, DMT, Ketamine, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 131

Forecast Period: 2026 - 2033

Market Size: $13000 million

CAGR: 15.1%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 131

Forecast Period: 2026 - 2033

Market Size: $13000 million

CAGR: 15.1%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Psychedelic Drugs Market Size | CAGR 15.1 Forecast 2033

Psychedelic Drugs Market Comprehensive Report: 200+ Pages | 2026–2034

🏭 Healthcare🌍 Global

Pages: 131

Forecast Period: 2026 - 2033

Market Size: $13000 million

CAGR: 15.1%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 131

Forecast Period: 2026 - 2033

Market Size: $13000 million

CAGR: 15.1%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Psychedelic Drugs Market Overview

The Psychedelic Drugs market refers to the industry involved in the research, development, and distribution of psychedelic substances for medical and therapeutic purposes. As the Psychedelic Drugs market size is expected to grow significantly, the growth outlook and market forecast are of paramount importance for industry stakeholders. The Psychedelic Drugs market is poised for industry expansion, driven by increasing demand for innovative treatments and rising investments in research and development. The current Psychedelic Drugs market size is approximately $1.5 billion, with a projected growth outlook of 15% per annum. The market forecast suggests that the industry will be shaped by key forces such as technology shifts, regulations, and consumer behavior.

Loading chart…

The Psychedelic Drugs market is expected to witness significant growth during the forecast period, driven by a CAGR of 15%. The largest region in the Psychedelic Drugs market is North America, while the fastest-growing region is expected to be Europe. Key forces shaping the industry include technology shifts, such as advancements in drug development and manufacturing, regulations, such as changes in government policies and laws, and consumer behavior, such as increasing demand for alternative treatments. As the industry continues to evolve, it is essential for stakeholders to stay informed about the latest trends, opportunities, and challenges in the Psychedelic Drugs market.

Report Overview

Report Attribute	Details
Market size value in 2025	13.00 billion
Revenue forecast in 2033	40.04 billion
Growth rate	CAGR of 15.1% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	COMPASS Pathways PLC; Pfizer; Eli Lilly; GlaxoSmithKline; Cybin Inc; Field Trip Health; ATAI Life Sciences; NUMINUS WELLNESS; MindMed; HAVN Life Sciences; Seelos Therapeutics; Jannsen; Acadia Pharmaceuticals; Intellipharmaceutics; Revive Therapeutics; Mydecine Innovations Group; Red Light Holland; Braxia Scientific; Mind Cure Health; Entheon Biomedical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Psychedelic Drugs market is poised for significant growth, driven by increasing demand for innovative treatments and shifting regulatory landscapes. The Psychedelic Drugs market size is expected to expand substantially, with a promising growth forecast, as major players invest heavily in research and development.

Growth Drivers2 items

Advances in psychedelic therapy research, leading to increased awareness and acceptance of Psychedelic Drugs as a viable treatment option for mental health disorders

Growing investments in the Psychedelic Drugs market, with key players forming strategic partnerships to accelerate product development and commercialization

Restraints2 items

Stringent regulatory frameworks, which can hinder the approval and commercialization of Psychedelic Drugs, thus limiting the growth of the Psychedelic Drugs market size

Public perception and stigma surrounding psychedelic substances, which can impact demand and adoption rates, affecting the overall growth forecast

Opportunities2 items

Expanding applications of Psychedelic Drugs beyond mental health, into areas such as pain management and neurological disorders, offering new revenue streams and growth avenues

Increasing focus on personalized medicine, with Psychedelic Drugs potentially offering tailored treatment options, driving innovation and growth in the Psychedelic Drugs market

Challenges2 items

Ensuring scalable and cost-effective production of Psychedelic Drugs, while maintaining quality and consistency, to meet growing demand and support the growth forecast

Addressing concerns around safety and abuse potential, through rigorous testing and regulatory oversight, to mitigate risks and protect the Psychedelic Drugs market size

Market Segmentation

Loading chart…

The Application segment of the Psychedelic Drugs market is a crucial aspect of the Psychedelic Drugs segmentation. This market can be divided into several subtypes, including treatment-resistant depression, anxiety disorders, post-traumatic stress disorder (PTSD), and addiction. Each subtype contributes to the overall Psychedelic Drugs market size, with treatment-resistant depression holding a significant share. The application segment is expected to drive the growth of the Psychedelic Drugs market, with the increasing adoption of psychedelic drugs in the treatment of mental health disorders.

The Types segment of the Psychedelic Drugs market is another essential aspect of the market taxonomy. This segment includes subtypes such as psilocybin, ketamine, LSD, and MDMA. Each subtype has its own unique characteristics and applications, contributing to the overall Psychedelic Drugs market size. Psilocybin, for instance, is being researched for its potential in treating depression and anxiety disorders, while ketamine is being used to treat treatment-resistant depression. The types segment is expected to play a significant role in shaping the future of the Psychedelic Drugs market, with ongoing research and development of new psychedelic drugs.

Psychedelic Drugs Segmentation Breakdown13 items

Application

Depressive Disorders

Post-Traumatic Stress Disorders

Substance Abuse Disorders

Obsessive Compulsive Disorders

Others

Types

Psilocybin

LSD

MDMA

DMT

Ketamine

Others

Regional Insights

Loading chart…

The Psychedelic Drugs market growth is poised to experience significant regional variations, with North America emerging as the largest region, accounting for approximately 40% of the global market. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing adoption of psychedelic therapies and growing investments in research and development.

Key drivers for North America include favorable policies, a mature ecosystem, and a high prevalence of mental health disorders. In Europe, drivers include increasing investments in psychedelic research, a growing demographics of patients seeking alternative therapies, and evolving policies supporting psychedelic therapies. Asia Pacific's growth is fueled by rising adoption of psychedelic therapies, expanding infrastructure, and growing investments in research and development. Latin America's growth is driven by increasing adoption and a growing ecosystem, while the Middle East & Africa region is expected to experience growth due to increasing investments and a rising demographics of patients seeking alternative therapies.

The regional forecast indicates that North America will maintain its dominance, while Asia Pacific will experience rapid growth, driven by the factors mentioned above. As the Psychedelic Drugs market continues to evolve, it is essential to monitor regional trends and developments to capitalize on emerging opportunities and stay ahead of the competition.

Competitive Landscape

The Psychedelic Drugs market exhibits a moderately consolidated structure, driven by a mix of global players and local companies. The Psychedelic Drugs competitive landscape is characterized by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players focus on product innovation and regulatory approvals, while local companies emphasize distribution and pricing strategies.

Companies in this market employ various strategies, including M&A, partnerships, product launches, expansion, R&D, and localization, to differentiate themselves. However, they face challenges such as margin pressure, compliance costs, and supply chain risks. To stay competitive, companies must develop unique value propositions, leveraging technology, service models, channel strength, customization, and cost advantages. The following companies have distinct strategic focuses:

COMPASS Pathways PLC: innovation pipeline

Pfizer: regional expansion

Eli Lilly: premium pricing

GlaxoSmithKline: OEM tie-ups

Cybin Inc: vertical integration

Field Trip Health: local manufacturing

Key Psychedelic Drugs Companies20 items

COMPASS Pathways PLC

Pfizer

Eli Lilly

GlaxoSmithKline

Cybin Inc

Field Trip Health

ATAI Life Sciences

NUMINUS WELLNESS

MindMed

HAVN Life Sciences

Seelos Therapeutics

Jannsen

Acadia Pharmaceuticals

Intellipharmaceutics

Revive Therapeutics

Mydecine Innovations Group

Red Light Holland

Braxia Scientific

Mind Cure Health

Entheon Biomedical

Market Ecosystem

The Psychedelic Drugs ecosystem spans a complex network of participants, from upstream technology providers and suppliers to downstream end users. This ecosystem can be broadly segmented into three main components: upstream, midstream, and downstream. The upstream segment comprises raw material suppliers and technology providers, while the midstream segment includes manufacturers and system integrators. The downstream segment, on the other hand, consists of distributors, channel partners, and end users, where value is ultimately captured.

Raw material suppliers — providing psychedelic compounds

Technology providers — developing formulation technologies

OEMs / manufacturers — producing psychedelic drugs

System integrators / EPCs — integrating psychedelic therapies

Distributors / channel partners — supplying psychedelic drugs

Regulators/standards bodies — overseeing safety and efficacy

End users / buyers — consuming psychedelic drugs for therapy

In the Psychedelic Drugs ecosystem, control points are largely influenced by regulators and standards bodies, who oversee the safety and efficacy of these drugs. Dependency risks also arise from input constraints, such as the availability of raw materials, and approvals from regulatory bodies. Furthermore, switching costs and partnerships between participants can impact the flow of value, while interoperability requirements may vary by region. A thorough value chain analysis is necessary to understand these dynamics and identify potential bottlenecks in the Psychedelic Drugs ecosystem.

Recent Industry Insights

The Psychedelic Drugs industry trends have witnessed significant developments over the last 12-18 months, shaping the future of the market. Recent partnerships between pharmaceutical companies and research institutions have accelerated the development of new psychedelic-based treatments. Notable mergers and acquisitions have also taken place, allowing companies to expand their portfolios and strengthen their positions in the market.

Additionally, several companies have launched new products and technologies, including innovative delivery systems and formulations. Regulatory changes, such as the FDA's breakthrough therapy designation for certain psychedelic-based treatments, have also contributed to the growth of the industry. Furthermore, a shift in consumer and enterprise trends has led to increased funding rounds and expansions, with investors showing growing interest in the potential of psychedelic drugs to address mental health disorders.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Psychedelic Drugs market outlook. The market attractiveness is moderate, driven by growing research and development activities. Competitive intensity is high, with several key players investing in clinical trials and product development. The long-term outlook is promising, with potential therapeutic applications in mental health treatment.

The innovation landscape is rapidly evolving, with advancements in psychedelic-assisted therapies. However, the demand–supply balance is a concern, with limited approved products and a shortage of skilled professionals. Key risk factors include regulatory uncertainties and potential side effects. Overall, the Psychedelic Drugs market is expected to experience significant growth, driven by increasing demand for novel therapeutic solutions.

11 items

1. Executive Summary

2. Psychedelic Drugs Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Psychedelic Drugs Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Psychedelic Drugs Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Depressive Disorders

6.1.2. Post-Traumatic Stress Disorders

6.1.3. Substance Abuse Disorders

6.1.4. Obsessive Compulsive Disorders

6.1.5. Others

6.2. Global Psychedelic Drugs Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Psilocybin

6.2.2. LSD

6.2.3. MDMA

6.2.4. DMT

6.2.5. Ketamine

6.2.6. Others

6.3. Global Psychedelic Drugs Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Psychedelic Drugs Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Psychedelic Drugs Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Psychedelic Drugs Market Competition by Key Manufacturers

8.1. Global Psychedelic Drugs Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Psychedelic Drugs: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. COMPASS Pathways PLC

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Pfizer

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Eli Lilly

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. GlaxoSmithKline

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Cybin Inc

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Field Trip Health

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. ATAI Life Sciences

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. NUMINUS WELLNESS

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. MindMed

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. HAVN Life Sciences

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Seelos Therapeutics

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Jannsen

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Acadia Pharmaceuticals

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Intellipharmaceutics

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Revive Therapeutics

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Mydecine Innovations Group

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Red Light Holland

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Braxia Scientific

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. Mind Cure Health

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

9.20. Entheon Biomedical

9.20.1. Company Basic Information and Sales Area

9.20.2. Main Business/Business Overview

9.20.3. Product Portfolio

9.20.4. Financial

9.20.5. Recent Industry Insights

9.20.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Psychedelic Drugs Market

Figure 4: Global Psychedelic Drugs Market: Drivers

Figure 5: Global Psychedelic Drugs Market: Challenges

Figure 6: Global Psychedelic Drugs Market: Trends

Figure 7: Global Psychedelic Drugs Market: Opportunity

Figure 8: Global Psychedelic Drugs Market: Restraint

Figure 9: Global Psychedelic Drugs Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Psychedelic Drugs Market Value (USD Million) By Region

Figure 15: Global Psychedelic Drugs Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Psychedelic Drugs Market Value (USD Million) By Region

Figure 23: Global Psychedelic Drugs Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

93 items

Table 1: Market Segmentation Analysis

Table 2: Global Psychedelic Drugs Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Psychedelic Drugs Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Psychedelic Drugs Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Psychedelic Drugs Market Value (USD Million) By Region

Table 10: Global Psychedelic Drugs Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Psychedelic Drugs Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Psychedelic Drugs Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Psychedelic Drugs Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: COMPASS Pathways PLC Basic Information And Sales Area

Table 31: COMPASS Pathways PLC. Products Portfolio

Table 32: Pfizer Basic Information And Sales Area

Table 33: Pfizer. Products Portfolio

Table 34: Eli Lilly Basic Information And Sales Area

Table 35: Eli Lilly. Products Portfolio

Table 36: GlaxoSmithKline Basic Information And Sales Area

Table 37: GlaxoSmithKline. Products Portfolio

Table 38: Cybin Inc Basic Information And Sales Area

Table 39: Cybin Inc. Products Portfolio

Table 40: Field Trip Health Basic Information And Sales Area

Table 41: Field Trip Health. Products Portfolio

Table 42: ATAI Life Sciences Basic Information And Sales Area

Table 43: ATAI Life Sciences. Products Portfolio

Table 44: NUMINUS WELLNESS Basic Information And Sales Area

Table 45: NUMINUS WELLNESS. Products Portfolio

Table 46: MindMed Basic Information And Sales Area

Table 47: MindMed. Products Portfolio

Table 48: HAVN Life Sciences Basic Information And Sales Area

Table 49: HAVN Life Sciences. Products Portfolio

Table 50: Seelos Therapeutics Basic Information And Sales Area

Table 51: Seelos Therapeutics. Products Portfolio

Table 52: Jannsen Basic Information And Sales Area

Table 53: Jannsen. Products Portfolio

Table 54: Acadia Pharmaceuticals Basic Information And Sales Area

Table 55: Acadia Pharmaceuticals. Products Portfolio

Table 56: Intellipharmaceutics Basic Information And Sales Area

Table 57: Intellipharmaceutics. Products Portfolio

Table 58: Revive Therapeutics Basic Information And Sales Area

Table 59: Revive Therapeutics. Products Portfolio

Table 60: Mydecine Innovations Group Basic Information And Sales Area

Table 61: Mydecine Innovations Group. Products Portfolio

Table 62: Red Light Holland Basic Information And Sales Area

Table 63: Red Light Holland. Products Portfolio

Table 64: Braxia Scientific Basic Information And Sales Area

Table 65: Braxia Scientific. Products Portfolio

Table 66: Mind Cure Health Basic Information And Sales Area

Table 67: Mind Cure Health. Products Portfolio

Table 68: Entheon Biomedical Basic Information And Sales Area

Table 69: Entheon Biomedical. Products Portfolio

Table 70: Global Market Value (USD Million) (2025-2032) By Application

Table 71: Global Market Share (%) By Application (2032)

Table 72: Global Market Value (USD Million) (2025-2032) By Types

Table 73: Global Market Share (%) By Types (2032)

Table 74: Global Psychedelic Drugs Market Value (USD Million) By Region

Table 75: Global Psychedelic Drugs Market Share (%) By Region (2025-2032)

Table 76: North America Market Value (USD Million) (2025-2032) By Country

Table 77: North America Market Value (USD Million) (2025-2032) By Application

Table 78: North America Market Value (USD Million) (2025-2032) By Types

Table 79: Europe Market Value (USD Million) (2025-2032) By Country

Table 80: Europe Market Value (USD Million) (2025-2032) By Application

Table 81: Europe Market Value (USD Million) (2025-2032) By Types

Table 82: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 83: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 84: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 85: South America Market Value (USD Million) (2025-2032) By Country

Table 86: South America Market Value (USD Million) (2025-2032) By Application

Table 87: South America Market Value (USD Million) (2025-2032) By Types

Table 88: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 89: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 90: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 91: Research Programs/Design For This Report

Table 92: Key Data Information From Secondary Sources

Table 93: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Psychedelic Drugs Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	13.00 billion
Revenue forecast in 2033	40.04 billion
Growth rate	CAGR of 15.1% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	COMPASS Pathways PLC; Pfizer; Eli Lilly; GlaxoSmithKline; Cybin Inc; Field Trip Health; ATAI Life Sciences; NUMINUS WELLNESS; MindMed; HAVN Life Sciences; Seelos Therapeutics; Jannsen; Acadia Pharmaceuticals; Intellipharmaceutics; Revive Therapeutics; Mydecine Innovations Group; Red Light Holland; Braxia Scientific; Mind Cure Health; Entheon Biomedical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options